Loading...
XSHE300639
Market cap523mUSD
Jan 10, Last price  
5.99CNY
1D
0.50%
1Q
-1.48%
IPO
38.96%
Name

Guangdong Hybribio Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300639 chart
P/E
27.35
P/S
3.48
EPS
0.22
Div Yield, %
3.93%
Shrs. gr., 5y
-1.50%
Rev. gr., 5y
13.73%
Revenues
1.10b
-80.27%
139,014,305182,717,806264,082,642344,833,859398,303,899479,085,119580,352,056729,392,8021,354,496,7592,673,022,9535,596,971,0561,104,453,848
Net income
140m
-91.86%
19,725,22329,169,94363,459,11465,212,17876,094,57893,210,017114,079,529147,290,874362,662,411852,160,1151,725,997,552140,472,219
CFO
327m
-75.01%
16,084,45822,890,92734,651,89648,469,07463,630,74879,165,08580,390,222112,831,785311,300,240631,341,7521,309,216,063327,233,676
Dividend
May 23, 20240.065 CNY/sh
Earnings
May 14, 2025

Profile

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.
URL
http://www.hybribio.cn/
IPO date
Apr 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,104,454
-80.27%
5,596,971
109.39%
Cost of revenue
934,618
2,565,395
Unusual Expense (Income)
NOPBT
169,836
3,031,576
NOPBT Margin
15.38%
54.16%
Operating Taxes
(31,698)
326,464
Tax Rate
10.77%
NOPAT
201,534
2,705,112
Net income
140,472
-91.86%
1,725,998
102.54%
Dividends
(150,900)
(101,936)
Dividend yield
2.88%
1.39%
Proceeds from repurchase of equity
(49,999)
BB yield
0.95%
Debt
Debt current
2,119
108,960
Long-term debt
63,073
61,069
Deferred revenue
11,820
14,132
Other long-term liabilities
11,866
1
Net debt
(1,539,920)
(1,376,724)
Cash flow
Cash from operating activities
327,234
1,309,216
CAPEX
(385,321)
Cash from investing activities
(292,850)
Cash from financing activities
(294,400)
FCF
138,469
1,655,198
Balance
Cash
1,071,987
1,411,832
Long term investments
533,125
134,920
Excess cash
1,549,889
1,266,904
Stockholders' equity
4,046,407
4,232,147
Invested Capital
3,608,504
3,742,388
ROIC
5.48%
86.58%
ROCE
3.25%
59.37%
EV
Common stock shares outstanding
561,889
651,685
Price
9.34
-16.85%
11.23
-14.35%
Market cap
5,248,042
-28.31%
7,320,591
-14.82%
EV
3,945,582
6,264,184
EBITDA
348,266
3,210,470
EV/EBITDA
11.33
1.95
Interest
6,097
8,183
Interest/NOPBT
3.59%
0.27%